Publication
Advancing clinical trials for rare renal cell carcinoma subtypes: Consensus statements from the International Kidney Cancer Symposium North America 2025 think tank.
Pavlos Msaouel, Salvatore La Rosa, Edwin Jason Abel, Laurence Albiges, Pedro C Barata, Stephanie A Berg, David A Braun, James Brugarolas, Matthew T Campbell, Marie I Carlo, Katie Coleman, Nicholas G Cost, Arighno Das, Arpita Desai, Nazli Dizman, Daniela Drago, Minas Economides, Daniel M Geynisman, Meghan Griffith, Tasha Hall, Elizabeth P Henske, Eric Jonasch, Prateek Khanna, Ritesh R Kotecha, Amy Luckenbaugh, Jodi K Maranchie, Viraj Master, Allison M May, Robert J Motzer, Moshe C Ornstein, Michael V Ortiz, Sumanta K Pal, Jose R Perez, Brian Rini, Daniel D Shapiro, Brian M Shuch, Adam E Singer, Eric A Singer, Walter M Stadler, Michael Staehler, Nizar M Tannir, Ulka N Vaishampayan, Wenxin Xu, Wesley Yip, Niki M Zacharias, Martin H Voss
- Source
- PubMed
- Retrieved
- Sep 30, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-PUBMED-20260930-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
PURPOSE: Rare renal cell carcinoma (RCC) subtypes present unique challenges for clinical trial design and drug development. This consensus initiative aimed to provide actionable expert guidance on advancing preclinical and clinical development of rational therapeutic strategies for non-clear cell…
Read on PubMedLinked entities
Linked entities (1)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Candidate 1
- cancerMalignant Kidney Neoplasmdictionary0.60
Curated evidence
Evidence citing this paper (0)
Data not yet available